Recently, the Cancer Support Community (CSC) conducted a survey to better grasp the challenges that patients, caregivers and clinical staff members face regarding immunotherapy. The goal is to ultimately use that information to craft an empowerment program that will improve the patient experience.
Ghassan K. Abou-Alfa, MD, shares his excitement over the use of immunotherapy for liver cancer in 2018, and highlights research initiatives that are studying its potential in combination with other therapies.
To help educate patients and enable health care teams to effectively manage these side effects, the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) issued new guidelines on understanding and managing immunotherapy-related toxicities.
Researchers from Israel, the United Kingdom (UK) and Canada sought to determine the cost-effectiveness of Keytruda for the second-line treatment of patients with advanced bladder cancer. Drug costs were compared between the US, UK, Canada and Australia.
Not all patients with non-small cell lung cancer (NSCLC) respond to immunotherapy, so researchers are exploring the use of combination regimens, including immune checkpoint inhibitors and chemotherapy, to improve outcomes in these patients.